Differences between zoledronic acid and denosumab for breast cancer treatment
Crossref DOI link: https://doi.org/10.1007/s00774-023-01408-z
Published Online: 2023-03-07
Published Print: 2023-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ishikawa, Takashi http://orcid.org/0000-0003-3450-4533
Text and Data Mining valid from 2023-03-07
Version of Record valid from 2023-03-07
Article History
Received: 30 January 2023
Accepted: 2 February 2023
First Online: 7 March 2023